NSEGeneral Updates1 Jul 2026 · 1 Jul 2026, 05:59 pm

General Updates

Medplus Health Services Limited · MEDPLUS

✦ AI Summary▼ NegativeRegulatory

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license for a store in Karnataka, resulting in a potential revenue loss of Rs 0.80 lacs.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Attachments (1)

📄

MEDPLUS_01072026175849_Intimation.pdf

pdf

Download →
View document text
MedPlus Health Services Limited July 01, 2026 The Listing Department The Listing Department BSE Limited N ational Stock Exchange of India Limited Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Fort, Plot No. C/1, G Block, Mumbai – 400001 Bandra - Kurla Complex BSE Scrip Code: 543427 Bandra (East), Mumbai – 400051 NSE Symbol: MEDPLUS Dear Sir/Madam, Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has received one suspension order for a Drug License of a store situated in the state of Karnataka: Pursuant to SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026, the details of the matter are as follows: Name(s) of the Nature and details of Date of receipt of Details of the Impact on Authority the action(s) taken, direction or order, violation(s)/ financial initiated or order(s) including any contravention(s) operation or passed interim or interim committed or other activities orders, or any other alleged to be of the listed communication committed entity, from the authority quantifiable in monetary terms to the extent possible Assistant Director, Suspension of Drug Order received on Under Rule 65 of Potential Drugs Control License for two days of 30.06.2026 Drugs and Revenue Loss of Administration, store situated at Cosmetics Act, Rs 0.80 lacs. Davanagere Circle, Anjaneya Layout 1940 and Drugs Karnataka. Davanagere and Cosmetics ,Karnataka. Rules, 1945 The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Kindly take the same on records. For MedPlus Health Services Limited Gangadi Madhukar Reddy Managing Director and Chief Executive Officer DIN: 00098097 040-6724 672 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com